Comparative evaluation of meglumine antimoniate encapsulated in a mixture of conventional and PEGylated liposomes and immunotherapy using an anti-canine IL-10 receptor-blocking monoclonal antibody on canine visceral leishmaniasis.
Nenhuma Miniatura disponível
Data
2022
Autores
Título da Revista
ISSN da Revista
Título de Volume
Editor
Resumo
This study compared the therapeutic potential of the chemotherapy using meglumine antimoniate encapsulated
in a mixture of conventional and PEGylated liposomes (Nano Sbv
) and immunotherapy with anti-canine IL-10
receptor-blocking monoclonal antibody (Anti IL-10R) on canine visceral leishmaniasis (CVL). Twenty mongrel
dogs naturally infected by L. infantum, displaying clinical signs of visceral leishmaniasis were randomly divided
in two groups. In the first one, nine dogs received six intravenous doses of a mixture of conventional and
PEGylated liposomes containing meglumine antimoniate at 6.5 mg Sb/kg/dose. In the second one, eleven dogs
received two intramuscular doses of 4 mg of anti-canine IL-10 receptor-blocking monoclonal antibody. The
animals were evaluated before (T0) and 30, 90, and 180 days after treatments. Our major results demonstrated
that both treatments were able to maintain hematological and biochemical parameters, increase circulating T
lymphocytes subpopulations, increase the IFN-γ producing T-CD4 lymphocytes, restore the lymphoproliferative
capacity and improve the clinical status. However, although these improvements were observed in the initial
post-treatment times, they did not maintain until the end of the experimental follow-up. We believe that the use
of booster doses or the association of chemotherapy and immunotherapy (immunochemotherapy) is promising to
improve the effectiveness of treating CVL for improving the clinical signs and possibly reducing the parasite
burden in dogs infected with Leishmania infantum.
Descrição
Palavras-chave
Leishamania infantum, Liposomal meglumine antimoniate, Chemotherapy
Citação
CARDOSO, J. M. de O. et al. Comparative evaluation of meglumine antimoniate encapsulated in a mixture of conventional and PEGylated liposomes and immunotherapy using an anti-canine IL-10 receptor-blocking monoclonal antibody on canine visceral leishmaniasis. Molecular Immunology, v. 141, p. 70-78, 2022. Disponível em: <https://www.sciencedirect.com/science/article/pii/S0161589021003217?via%3Dihub>. Acesso em: 11 out. 2022.